Assessment of serum glucagon-like peptide-1 and dipeptidyl peptidase-4 levels in patients with migraine
- 26.09.2025
- Research
- Verfasst von
-
Melis Gultekin
Korrespondierender Autor Melis Gultekin
- Faculty of Medicine, Department of Physiology, Düzce University, 81620, Düzce, Turkey
-
Fatih Davran
Fatih Davran
- Department of Biochemistry, Düzce Akçakoca State Hospital, Düzce, Turkey
-
Nehir Yuksel
Nehir Yuksel
- Faculty of Medicine, Department of Public Health, Kırklareli University, Kırklareli, Turkey
-
Ozge Beyazcicek
Ozge Beyazcicek
- Faculty of Medicine, Department of Physiology, Düzce University, 81620, Düzce, Turkey
-
Serif Demir
Serif Demir
- Faculty of Medicine, Department of Physiology, Düzce University, 81620, Düzce, Turkey
- Erschienen in
- Acta Neurologica Belgica | Ausgabe 6/2025
Abstract
Background
Migraine is a prevalent neurovascular disorder affecting over one billion people globally, imposing significant daily life limitations. Migraine headaches are linked to the activation of trigeminal nerve endings. Glucagon-like peptide-1 (GLP-1) is a hormone involved in insulin regulation and plays neuroprotective roles in the central nervous system (CNS). Dipeptidyl peptidase-4 (DPP-4) is a protease enzyme that degrades GLP-1, rendering it inactive, and modulates metabolic and neurological pathways. This study investigates the association between serum GLP-1 and DPP-4 levels and migraine pathophysiology to propose a novel therapeutic approach for migraine.
Methods
The study included 42 migraine patients and 42 healthy controls. After fasting for at least 8 h, blood samples were collected. Serum GLP-1 and DPP-4 levels were measured using ELISA, and statistical analyses were conducted with SPSS 24.0.
Results
Serum GLP-1 and DPP-4 levels were significantly lower in migraine patients compared to controls (p < 0.001). Patients with migraine with aura had significantly lower GLP-1 levels compared to those with migraine without aura (p = 0.016). A significant decrease in GLP-1 levels was observed in patients experiencing pain localized in the occipital lobe (p = 0.01).
Conclusions
Serum GLP-1 and DPP-4 levels were lower in migraine patients. Given the role of GLP-1 in the central nervous system, reduced GLP-1 may contribute to migraine pain. Similarly, low DPP-4, which metabolizes GLP-1, may be linked to these findings and could trigger attacks by increasing blood CGRP levels.
Anzeige
- Titel
- Assessment of serum glucagon-like peptide-1 and dipeptidyl peptidase-4 levels in patients with migraine
- Verfasst von
-
Melis Gultekin
Fatih Davran
Nehir Yuksel
Ozge Beyazcicek
Serif Demir
- Publikationsdatum
- 26.09.2025
- Verlag
- Springer International Publishing
- Erschienen in
-
Acta Neurologica Belgica / Ausgabe 6/2025
Print ISSN: 0300-9009
Elektronische ISSN: 2240-2993 - DOI
- https://doi.org/10.1007/s13760-025-02894-w
Dieser Inhalt ist nur sichtbar, wenn du eingeloggt bist und die entsprechende Berechtigung hast.